ABBV-932 is under clinical development by AbbVie and currently in ... a DRD2 and DRD3 dopamine receptor modulator and is administered through oral route in the form of capsule. AbbVie is a specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback